Bryan Garcia
Pulmonary Disease · Birmingham, ALNPI 1700146685
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,576 of the $28,970 with a category attached, or 74.5%. Insmed, Inc. accounts for 60.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $14,792 and has fallen 64.1% since, to $5,304 in 2025. Among pulmonary disease clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 45 payments — averaging $643.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$17K
- Mannkind Corporation$5K
- Vertex$3K
- Mylan Specialty L.p.$3K
- Electromed, Inc.$397
- Viatris Specialty LLC$122
- plus $204 from 5 others
Across 43 payments — averaging $13,430 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mannkind Corporation$318K
- AstraZeneca$131K
- Vertex$98K
- Paratek Pharmaceuticals, Inc.$31K
What the payments were for
- Consulting fees$21,57674%
- Speaking & faculty fees$4,50016%
- Travel & lodging$1,2374%
- Food & beverage$1,5415%
- Education$1160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 26 | $17,400 |
| Mannkind Corporation | 2 | $5,060 |
| Vertex | 1 | $3,150 |
| Mylan Specialty L.p. | 3 | $2,637 |
| Electromed, Inc. | 6 | $397 |
| Viatris Specialty LLC | 1 | $122 |
| AbbVie | 1 | $74 |
| GSK | 2 | $50 |
| Novartis | 1 | $31 |
| Genentech USA, Inc. | 1 | $30 |
| Dexcom, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$5,474
- TOBI Podhaler$2,742
- SMARTVEST$118
How this compares
$28,970 in reported general payments places this provider in the 95th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 21 | $303,513 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $17,444 |
| Azithromycin | 244 | $9,308 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,486 |
| Ethambutol Hcl | 81 | $5,259 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $4,866 |
| Amikacin Sulfate | 47 | $4,490 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $2,320 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $2,240 |
| Rifampin | 26 | $1,193 |
| Levofloxacin | 30 | $441 |
| Pantoprazole Sodium | 23 | $424 |
| Prednisone | 53 | $128 |
| Famotidine | 20 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Insmed, Inc.Arikayce | $17,400 | $303,51321 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $50 | $23,93038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Birmingham
- Tejaswini KulkarniBirmingham$134K
- Amanda DenhamBirmingham$45K
- Steven RoweBirmingham$27K
- Peter MorrisBirmingham$25K
- Russell BeatyBirmingham$24K
- Jay HeideckerBirmingham$21K
- Jennifer TrevorBirmingham$19K
- Jason FainBirmingham$18K
- Jeffrey GarnerBirmingham$14K
- Brian FlanaganBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.